Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Okta, Inc. (OKTA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Okta, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Okta, Inc. trades at $139.34 (market cap $24.09B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Okta, Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | OKTA | |
|---|---|---|
Market Cap | $39.89B | $24.09B |
Sector | Health | Technology |
52-Week High | $491.22 | $148.84 |
52-Week Low | $278.09 | $62.93 |
Enterprise Value | $38.15B | $21.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
OKTA trades at $138.63, down 6.86% today, but maintains strong technical momentum with bullish moving averages and recent AI-driven demand boosting cybersecurity stocks. The company shows improving fundamentals with revenue growth to $2.61B in 2025 and three consecutive quarterly EPS beats. Positive sentiment is driven by AI security adoption and institutional interest, though high valuations (P/E 100.46) and overbought RSI levels warrant caution.
Outlook remains positive with AI security demand accelerating revenue growth and improving profitability (2026 net margin projected at 8.24%). Key risks include intense cybersecurity competition and valuation concerns. Analyst consensus is strongly bullish (73% buy ratings) with $124.08 price target, though current price exceeds consensus suggesting near-term consolidation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
